GRAIL Inc's stock surged 9.13% during intraday trading on Wednesday, marking a significant upward movement.
The sharp rise appears driven by positive analyst sentiment, with multiple firms reiterating favorable ratings on the healthcare company. Canaccord Genuity maintained its Buy rating with an $80 price target, while Guggenheim also reiterated a Buy rating with a $75 price target. Piper Sandler maintained a Hold rating with a $56 price target.
The collective analyst actions, particularly the bullish price targets from Canaccord Genuity and Guggenheim, likely fueled investor confidence and buying activity during the session.